Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for S. Aureus Bacteremia (DOTS)
NCT04775953Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dalbavancin in Staphylococcus aureus bacteremia (SAB), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2021; status: completed.
02
Drugs
dalbavancin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT04775953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775953.